AstraZeneca to Highlight Tagrisso’s Clinical Data for NSCLC at ELCC 2025

Shots: AstraZeneca to present Tagrisso’s data from P-III (LAURA & FLAURA2) & P-II (SAVANNAH & ORCHARD) trials at ELCC 2025 for EGFRm NSCLC pts who failed or received 1L therapy; data to support global filings In LAURA, Tagrisso showed favorable OS trend (mOS: 58.8 vs 54.1mos.; maturity: 31%) despite 78% of PBO pts receiving it…

ByRidhi RastogiMarch 25, 2025

NEWS

BMS Reports the EC’s Approval of Breyanzi to Treat R/R Follicular Lymphoma

Shots: The EC has approved Breyanzi for r/r follicular lymphoma adults treated with ≥2 previous lines of systemic therapy in 30 EEA states Approval was based on global P-II (TRANSCEND FL) study, assessing Breyanzi’s safety & efficacy to treat r/r indolent B-cell NHL incl. FL In pts treated in 3L+ setting, study met…

ByRidhi RastogiMarch 17, 2025

NEWS

Ono Pharma and Ionis Enter into License Agreement for Sapablursen to Treat Polycythemia Vera

Shots: Ionis has granted Ono Pharma an exclusive global license to develop & commercialize sapablursen for the treatment of polycythemia vera (PV) As per the deal, Ionis will get $280M upfront & ~$660M in development, regulatory & sales milestones, plus mid-teens net sales-based royalties as well as Ionis will be responsible to complete ongoing…

ByRidhi RastogiMarch 12, 2025

NEWS

HUTCHMED Reports Enrollment Completion in P-II Trial of Fanregratinib for Intrahepatic Cholangiocarcinoma in China

Shots: HUTCHMED has reported enrollment completion in P-II trial of fanregratinib to treat intrahepatic cholangiocarcinoma (IHCC) in pts with FGFR2 fusion or rearrangement; favorable trial results will support NMPA’s NDA submission The P-II trial of fanregratinib will assess ORR as 1EP whereas PFS, DCR, DoR, & OS as 2EPs in pts (n=87). Topline data…

ByRidhi RastogiMarch 7, 2025

EXCLUSIVE

Exclusive: David Esposito in an Illuminating Discussion with PharmaShots

Shots: Our recent Spotlight interview with David Esposito, CEO at ONL therapeutics became a major hit on the internet. We were moved by the overwhelming response from the netizens Here we have again, David Esposito in an engaging conversation with PharmaShots. David discusses in great length about the company’s lead candidate ONL1204, currently being evaluated…

ByHimanshu SehgalMarch 12, 2024

VIEWPOINTS

PharmaShots Interview: Astellas’ Dr. Andrew Krivoshik Shares Insights on P-II FAST Study of Zolbetuximab

In an interview with PharmaShots, Dr. Andrew Krivoshik, Senior Vice President and Oncology Therapeutic Area Head at Astellas, shared his views on the P-II FAST study result published in the journal Gastric Cancer and highlights the data published in Annals of Oncology. Shots: The data from P-II FAST study evaluating zolbetuximab + EOX in 1L patients with advanced gastric and…

BySenior EditorJuly 26, 2021

AstraZeneca to Highlight Tagrisso’s Clinical Data for NSCLC at ELCC 2025

BMS Reports the EC’s Approval of Breyanzi to Treat R/R Follicular Lymphoma

Ono Pharma and Ionis Enter into License Agreement for Sapablursen to Treat Polycythemia Vera

HUTCHMED Reports Enrollment Completion in P-II Trial of Fanregratinib for Intrahepatic Cholangiocarcinoma in China

Exclusive: David Esposito in an Illuminating Discussion with PharmaShots

PharmaShots Interview: Astellas’ Dr. Andrew Krivoshik Shares Insights on P-II FAST Study of Zolbetuximab

Contact US

FOLLOW US